Medical Condition

large b cell lymphoma

Total Trials

7

Recruiting Now

7

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — large b cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for large b cell lymphoma?

ClinicalMetric currently tracks 7 actively recruiting clinical trials for large b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for large b cell lymphoma?

large b cell lymphoma research spans Phase 1 (4 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a large b cell lymphoma clinical trial?

Eligibility criteria for large b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Washington University School of Medicine 1 trial

Cancer Research UK 1 trial

Malaghan Institute of Medical Research 1 trial

Estrella Biopharma, Inc. 1 trial

Allogene Therapeutics 1 trial

Recruiting Clinical Trials

NCT07052305 Phase 1

Recruiting

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School o...

View Trial →

NCT06045910 Phase 1, Phase 2

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Malaghan Institute of Medical ...

View Trial →

NCT06343311 Phase 1, Phase 2

Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Estrella Biopharma, Inc.

View Trial →

NCT06500273 Phase 2

Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Enrollment

250 pts

Location

United States, Austr...

Sponsor

Allogene Therapeutics

View Trial →

NCT07236203

Recruiting

Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Related Conditions

lymphoma non hodgkin (2) non hodgkin lymphoma (2) lymphoma large b cell diffuse (1) lymphoma mantle cell (1) lymphoma follicular (1) lymphoma b cell (1) diffuse large b cell lymphoma not otherwise specified (1) primary mediastinal large b cell lymphoma pmbcl (1) transformed non hodgkin lymphoma (1) b cell non hodgkin s lymphoma nhl (1) lymphoma non hodgkins (1) lymphomas non hodgkin s b cell (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology